| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | 4F2; CD98; MDU1; 4F2HC; 4T2HC; NACAE; CD98HC |
| WB Predicted band size | 68 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SLC3A2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC3A2抗体的3篇示例文献(内容为虚构示例，仅作格式参考)：
1. **文献名称**: "SLC3A2/CD98hc as a Biomarker in Tumor Angiogenesis and Metastasis"
**作者**: Prasad, R. et al.
**摘要**: 研究通过免疫组化及Western blot分析，发现SLC3A2在多种实体瘤中高表达，其抗体阻断实验表明SLC3A2通过调控整合素信号通路促进肿瘤血管生成和转移，提示其作为治疗靶点的潜力。
2. **文献名称**: "Structural Insights into SLC3A2-CD98 Complex and Antibody Recognition"
**作者**: Yan, L. et al.
**摘要**: 通过冷冻电镜解析SLC3A2与CD98轻链的复合物结构，揭示其介导氨基酸转运的分子机制。研究利用特异性抗体验证关键表位，为开发靶向SLC3A2的抗体药物提供结构基础。
3. **文献名称**: "SLC3A2 Antibody Blocks Viral Entry by Disrupting Integrin β1 Interaction"
**作者**: Coyne, C.B. et al.
**摘要**: 发现SLC3A2作为某些肠道病毒的宿主受体，其抗体可竞争性抑制病毒与细胞表面整合素β1的结合，阻断病毒内化，为抗病毒治疗提供新策略。
4. **文献名称**: "Targeting SLC3A2 in Immune Checkpoint Therapy-Resistant Cancers"
**作者**: Kim, S. et al.
**摘要**: 研究显示，SLC3A2抗体联合PD-1抑制剂可增强T细胞对耐药肿瘤的杀伤作用，机制涉及SLC3A2对肿瘤微环境中T细胞代谢的重编程作用。
(注：以上文献信息为模拟生成，实际引用需查询真实数据库如PubMed或Google Scholar。)
The SLC3A2 antibody targets the solute carrier family 3 member 2 (SLC3A2), a transmembrane glycoprotein also known as CD98 or 4F2. SLC3A2 is a key component of heterodimeric amino acid transporters, forming complexes with light chains like SLC7A5 (LAT1) or SLC7A8 (LAT2) to mediate cellular uptake of neutral and cationic amino acids. These transporters play critical roles in nutrient sensing, cell growth, and immune regulation. SLC3A2 is ubiquitously expressed, particularly in proliferating cells, and is overexpressed in various cancers, where it supports tumor metabolism and metastasis.
SLC3A2 antibodies are widely used in research to study protein expression, localization, and function in normal and pathological contexts. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry. Research highlights its involvement in mTOR signaling, T-cell activation, and tumor microenvironment adaptation. Dysregulation of SLC3A2 is linked to cancer progression, autoimmune disorders, and metabolic diseases, making it a potential therapeutic target.
Antibodies against SLC3A2 also aid in exploring its role in cell adhesion, as the protein interacts with integrins to regulate intracellular signaling pathways. Studies using these antibodies have advanced understanding of its dual roles in amino acid transport and integrin-mediated signaling, emphasizing its importance in cellular physiology and disease mechanisms.
×
